Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01255462 | Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration | PHASE1 | COMPLETED | 24 | — | — | Nov 1, 2010 | Sep 1, 2011 | May 1, 2012 | 8 | United States |
| Arm | Type | Description |
|---|---|---|
| LFG316 0.15mg | EXPERIMENTAL | - |
| LFG316 0.5mg | EXPERIMENTAL | - |
| LFG316 1.5mg | EXPERIMENTAL | - |
| LFG316 5mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LFG316 | BIOLOGICAL | - |
Inclusion Criteria: * Male or female AMD patients 55 to 90 years old, inclusive. In either eye, diagnosis of geographic atrophy or choroidal neovascularization due to AMD * ETDRS best corrected visual acuity of 60 letters or worse in the study eye. Exclusion Criteria: * Retinal disease other than...